InvestSMART

Australian Clinical Labs Limited (ASX:ACL)

ALERT: Price-sensitive ASX Announcement for ACL
Current share price for ACL : $2.230 -0.19 (-7.85%)+
Announcement
Release
16 Feb 2026 8:10AM
Price at Release
$2.420
Full Release
download
Summary
Australian Clinical Labs Limited (ACL) reported its 1H26 financial results, highlighting improved earnings quality despite challenging market conditions. Revenue was slightly down by 1% compared to the previous corresponding period, primarily due to market growth being below average and a strategic optimization of commercial contracts. However, ACL achieved a 2.4% increase in underlying EBIT and an 8.9% growth in underlying NPAT, attributed to closing loss-making ACCs, operational efficiencies, and AI-driven productivity improvements. The company declared an interim fully franked dividend of 3.75 cents per share, representing 55% of underlying NPAT. ACL also announced a continuation of its share buyback program and provided updated FY26 guidance, anticipating revenue between $735m and $745m. ACL plans strategic initiatives to support future growth and reinforce its competitive advantage, including expanding non-Medicare services and implementing AI and automation.
Key Points
  • Revenue decreased by 1.0% compared to the previous corresponding period.
  • Underlying EBIT increased by 2.4%, and margins expanded by 30 basis points.
  • Underlying NPAT grew by 8.9% due to operational efficiencies and AI-driven productivity improvements.
  • Interim fully franked dividend of 3.75 cents per share declared.
  • Continued share buyback with $27.8m returned to shareholders in 1H26.
  • Updated FY26 revenue guidance of $735m to $745m.
  • Operational efficiency improvements include AI and automation projects.
  • Focus on strategic non-Medicare service expansion and digitalisation initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.